GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Eupraxia Pharmaceuticals Inc (TSX:EPRX) » Definitions » Equity-to-Asset

Eupraxia Pharmaceuticals (TSX:EPRX) Equity-to-Asset : 0.11 (As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is Eupraxia Pharmaceuticals Equity-to-Asset?

Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Eupraxia Pharmaceuticals's Total Stockholders Equity for the quarter that ended in Dec. 2023 was C$2.22 Mil. Eupraxia Pharmaceuticals's Total Assets for the quarter that ended in Dec. 2023 was C$20.27 Mil.

The historical rank and industry rank for Eupraxia Pharmaceuticals's Equity-to-Asset or its related term are showing as below:

TSX:EPRX' s Equity-to-Asset Range Over the Past 10 Years
Min: -14.59   Med: 0.11   Max: 1.02
Current: 0.11

During the past 7 years, the highest Equity to Asset Ratio of Eupraxia Pharmaceuticals was 1.02. The lowest was -14.59. And the median was 0.11.

TSX:EPRX's Equity-to-Asset is ranked worse than
81.79% of 1565 companies
in the Biotechnology industry
Industry Median: 0.67 vs TSX:EPRX: 0.11

Eupraxia Pharmaceuticals Equity-to-Asset Historical Data

The historical data trend for Eupraxia Pharmaceuticals's Equity-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Eupraxia Pharmaceuticals Equity-to-Asset Chart

Eupraxia Pharmaceuticals Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Equity-to-Asset
Get a 7-Day Free Trial -5.39 -14.59 0.65 0.41 0.11

Eupraxia Pharmaceuticals Quarterly Data
Dec17 Dec18 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Jun23 Sep23 Dec23
Equity-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.65 0.41 0.37 0.50 0.11

Competitive Comparison of Eupraxia Pharmaceuticals's Equity-to-Asset

For the Biotechnology subindustry, Eupraxia Pharmaceuticals's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Eupraxia Pharmaceuticals's Equity-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Eupraxia Pharmaceuticals's Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where Eupraxia Pharmaceuticals's Equity-to-Asset falls into.



Eupraxia Pharmaceuticals Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

Eupraxia Pharmaceuticals's Equity to Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Equity to Asset (A: Dec. 2023 )=Total Stockholders Equity/Total Assets
=2.216/20.266
=

Eupraxia Pharmaceuticals's Equity to Asset Ratio for the quarter that ended in Dec. 2023 is calculated as

Equity to Asset (Q: Dec. 2023 )=Total Stockholders Equity/Total Assets
=2.216/20.266
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Eupraxia Pharmaceuticals  (TSX:EPRX) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.


Eupraxia Pharmaceuticals Equity-to-Asset Related Terms

Thank you for viewing the detailed overview of Eupraxia Pharmaceuticals's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Eupraxia Pharmaceuticals (TSX:EPRX) Business Description

Traded in Other Exchanges
Address
201-2067 Cadboro Bay Road, Victoria, BC, CAN, V8R 5G4
Eupraxia Pharmaceuticals Inc is a clinical-stage biotechnology company focused on the development of locally delivered, extended-release alternatives to existing pharmaceuticals. Its product EP-104 is used for the treatment of osteoarthritis and eosinophilic esophagitis symptoms.